View metadata, citation and similar papers at core.ac.uk

brought to you by CORE

provided by e_Buah - Biblioteca Digital de la Universidad de Alcalá

Document downloaded from the institutional repository of the University of Alcala: https://ebuah.uah.es/dspace/

This is a postprint version of the following published document:

Prados, Isabel M et al., 2020. Identification of Peptides Potentially Responsible for In Vivo Hypolipidemic Activity of a Hydrolysate from Olive Seeds. Journal of agricultural and food chemistry, 68(14), pp.4237–4244.

Available at https://doi.org/10.1021/acs.jafc.0c01280

© 2020 American Chemical Society

(Article begins on next page)

This work is licensed under a

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

1 **IDENTIFICATION OF PEPTIDES POTENTIALLY RESPONSIBLE FOR *IN***
2 ***VIVO*** **HYPOLIPIDEMIC ACTIVITY OF A HYDROLYSATE FROM OLIVE**
3 **SEEDS**

4

5 Isabel M. Prados[1], J. M. Orellana[2], M. Luisa Marina[1,3], M. Concepción García[1,3]*

6

7 [1]Departamento de Química Analítica, Química Física e Ingeniería Química, Facultad de
8 Ciencias, Universidad de Alcalá, Ctra. Madrid-Barcelona Km. 33.600, 28871 Alcalá de
9 Henares (Madrid), Spain.

10 [2]Centro de Experimentación Animal, Universidad de Alcalá, Ctra. Madrid-Barcelona
11 Km. 33.600, 28871 Alcalá de Henares (Madrid), Spain.

12 [3]Instituto de Investigación Química "Andrés M. del Rio" (IQAR), Universidad de
13 Alcalá, Ctra. Madrid-Barcelona Km. 33.600, 28871 Alcalá de Henares (Madrid), Spain.

14

15

16 * Corresponding author

17 concepcion.garcia@uah.es

18 P: +34 918854915

19

20 **ABSTRACT**

21 Previous studies demonstrated that peptides produced by the hydrolysis of olive
22 seed proteins using Alcalase enzyme showed *in vitro* multifunctional lipid-lowering
23 capability. This work presents a deeper insight in the hypolipidemic effect of olive seed
24 peptides. The capability of olive seed peptides to inhibit endogenous cholesterol
25 biosynthesis through the inhibition of HMG-CoA reductase enzyme was evaluated
26 observing a 38 ± 7% of inhibition in comparison with a blank. Two *in vivo* assays using
27 different peptides concentrations were designed to evaluate the hypolipidemic effect of
28 olive seed peptides in male and female mice. A low concentration of hydrolysate (200
29 mg/kg/day) reduced total cholesterol in male mice in a 20% after 11 weeks treatment
30 compared to the mice feeding the hypercholesterolemic diet. A higher hydrolysate
31 concentration (400 mg/kg/day) showed a greater reduction in total cholesterol (25%).
32 Hypocholesterolemic effect was attributed to the capacity of the hydrolysate to increase
33 HDL cholesterol and to decrease LDL cholesterol. The analysis of the olive seed
34 hydrolysate by RP-HPLC-MS/MS enabled the identification of peptides that could be
35 responsible for this hypolipidemic effect.

36

37 **Keywords:** Hypolipidemic activity, peptides, *in vivo* assay, olive seed, mass
38 spectrometry.

39

40 ## 1. Introduction

41 Cardiovascular diseases are a serious worldwide health problem. Indeed, above 42 31 % of all world deaths are due to these diseases.[1] Main risk factor in the development 43 of cardiovascular diseases is hyperlipidemia, characterized by high serum triglycerides 44 and cholesterol levels.

45 There are different strategies to treat hyperlipidemia. Most of these strategies are 46 based on the disruption of micellar cholesterol transport and the inhibition of enzymes 47 involved in the absorption and biosynthesis of cholesterol and triglycerides. In fact, 48 cholesterol is solubilised in micelles for its transportation and absorption and, thus, the 49 displacement of cholesterol in micelles has been a target to decrease cholesterol 50 absorption.[2] Moreover, the inhibition of the pancreatic cholesterol esterase enzyme, that 51 hydrolysates dietary cholesterol esters into free cholesterol, also results in the reduction 52 of the bioavailability of dietary cholesterol esters.[3] Additionally, oxidation of endogenous 53 cholesterol produces bile acids in the liver and the sequestering of bile acids has been an 54 additional strategy to decrease plasma cholesterol level.[4] Regarding triglycerides, their 55 absorption can be ameliorated by the inhibition of pancreatic lipase enzyme that is 56 responsible for their hydrolysis into monoglycerides and free fatty acids.[5] Furthermore, 57 biosynthesis of endogenous cholesterol consists of different cascade reactions and a 58 proposed mechanism to disrupt cholesterol biosynthesis is based on the inhibition of the 59 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA, EC 1.1.1.34) reductase enzyme 60 that catalyses the rate-limiting step in this process.[6]

61 Different synthetic drugs based on previous strategies (inhibitors of cholesterol 62 endogenous synthesis, inhibitors of membrane proteins that promote the intestinal 63 absorption of cholesterol, bile acid sequestrants, etc.) have been developed for the 64 treatment of hyperlipidemia. However, these drugs can cause diverse side effects

65 including digestive disturbances, nausea, increase of hepatic transaminases and creatine
66 kinase, muscle weakness, headache, *etc.*[7,8] On the other hand, there is an increasing
67 interest in searching for alternative natural compounds to treat and/or prevent
68 hyperlipidemia. Different authors have demonstrated that peptides from soybean, lupin,
69 rice bran, potato, seafood, and fish[9-10] could exert *in vitro* hypolipidemic activity. An
70 additional source of lipid-lowering peptides are some food by-products. Moreover, the
71 exploitation of food by-products contributes to the sustainability of food processing. As
72 example, our research group demonstrated, in a previous work, that peptides from olive
73 seeds proteins presented *in vitro* multifunctional lipid-lowering capacity. Indeed, olive
74 seed peptides could decrease exogenous lipid absorption by the reduction of the micellar
75 cholesterol solubility and the inhibition of cholesterol esterase and pancreatic lipase
76 enzymes.[11]

77 Despite *in vitro* experiments are useful as a preliminary evaluation of potential
78 bioactivity, physiological processes and components bioavailability can make that *in vitro*
79 activity was not correlated with results at *in vivo* level. The main aim of this work was to
80 further investigate the hypolipidemic capacity of the olive seed hydrolysate by studying
81 its capacity to inhibit the biosynthesis of cholesterol, its cytotoxicity, and its effect at
82 physiological level. Moreover, peptides potentially responsible of this effect were
83 identified by HPLC-MS/MS.

84

2. Materials and methods

2.1 Chemicals

Water was obtained with a Milli-Q system from Millipore (Bedford, MA, USA). Acetone, hydrochloric acid (HCl), acetonitrile (ACN), and acetic acid (AA) were obtained from Scharlau (Barcelona, Spain). Tris(hydroxymethyl)aminomethane (Tris), sodium dodecyl sulfate (SDS), and di-sodium tetraborate were from Merck (Darmstadt, Germany). DL-dithiothreitol (DTT), albumin from bovine serum (BSA), β-mercaptoethanol, o-phthaldialdehyde (OPA), L-glutathione (GSH), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), Dulbecco's modified eagle's medium (DMEM), antibiotics (penicillin, streptomycin, and amphotericin), fetal bovine serum, phosphate buffered (PB), and the HMGCoA-reductase (HMGR) assay kit were purchased in Sigma-Aldrich (St. Louis, MO, USA). Bradford reagent (Coomassie Blue G-250) was acquired at Bio-Rad (Hercules, CA, USA). All the chemicals were analytical grade, except for ACN and AA, which were MS grade. Ezetimibe was obtained from Merck Sharp & Dohme (Kenilworth, NJ, USA) and Alcalase 2.4 L FG (EC 3.4.21.62) was kindly donated by Novozymes Spain S.A. (Madrid, Spain). All cell lines (HeLa and HK-2) were from the American Type Culture Collection (Rockwell, MD, USA).

2.2 Production of hydrolysate

Raw olives of 'Manzanilla' variety were kindly donated by the olive company FAROLIVA S.L. (Murcia, Spain). Olive seeds were extracted from olive stones by manual pressing. Olive seeds were next ground in a domestic mill and defatted with hexane for 30 min (four times). Defatted seeds were dried at room temperature. Seed

109 proteins were extracted and digested following the method described by Prados et al.[11]
110 Briefly, 0.03 g of deffated olive seed were mixed with 5 mL of 0.1 M Tris-HCl buffer
111 containing 0.5% SDS and 0.5% DTT (pH 7.5). For that purpose, a high intensity focus
112 ultrasonic (HIFU) probe (model VCX130, Sonic Vibra-Cell, Hartford, CT, USA) was
113 employed at a 30% of amplitude for 5 min. After centrifugation of the extract at 6000g
114 for 10 min, supernatant containing proteins was collected. Proteins were next precipitated
115 with cold acetone for 24 h followed by centrifucation and drying. Finally, proteins were
116 dissolved in a 5 mM borate buffer (pH 8.5) and hydrolyzed with Alcalase at 50 ºC for 4
117 h. Protein concentration was estimated by Bradford assay[12] and content of peptides was
118 determined using OPA assay.[11]

119

120 *2.3 HMGR in vitro assay*

121 HMGR inhibition assay was carried out following the method used by Marques
122 et al.[13] HMGR assay kit included the assay buffer, pravastatin, β-nicotinamide adenine
123 dinucleotide 2'-phosphate reduced tetrasodium salt hydrate (NADPH), HMGCoA, and
124 HMGR enzyme. Solutions containing 181 µL of the assay buffer (diluted 5 times), 1 µL
125 of inhibitor (pravastatin/sample), 4 µL of NADPH, 12 µL of HMGCoA, and 2 µL of
126 HMGR enzyme were prepared. After mixing the sample thoroughly, the absorbance of
127 the NADPH was measured every 10 s up to 10 min at a wavelength of 340 nm. The
128 activity (A) of HMGR, expressed as µmol of oxidized NADPH/min/mg protein, was
129 calculated using the following equation:

130
$$A = \frac{(Abs_{340}/min_{sample} - Abs_{340}/min_{blank}) \cdot TV}{12.44 \cdot V \cdot 0.6 \cdot LP}$$

131 where TV is the total volume (mL), V is the volume of enzyme (mL), 0.6 is the enzyme
132 concentration in mg protein/mL, LP is the light path (cm), 12.44 is the product of the
133 molar absorption coefficient of NADPH at 340 nm (6.22 mM^{-1} cm^{-1}) by two (number of
134 NADPH molecules consumed in the reaction), Abs_{340}/min_{sample} is the absorbance
135 observed when adding the hydrolysate, and Abs_{340}/min_{blank} is the absorbance
136 corresponding to the blank. Each sample was measured by triplicate. Two different
137 concentrations of hydrolysate were measured, 3.1 mg/mL and 26.7 mg/mL. The
138 percentage of inhibition of HMGR was calculated as:

139 $$\% \text{ inhibition of HMGR} = \frac{A_{máx} - A_{sample}}{A_{máx}} \times 100$$

140 where $A_{máx}$ is the activity of the enzyme without inhibitor and A_{sample} is the activity of the
141 enzyme when adding sample or pravastatin.

142

143 *2.4 Cytotoxicity of the olive seed hydrolysate*

144 The MTT assay was carried out following the method described by Prados et al.[11]
145 Different concentrations of the olive seed hydrolysate were used, and two different cell
146 lines were employed: a cancer cell line (HeLa, human cervical cancer cells) and a healthy
147 cell line (HK-2, human renal proximal tubule cells). Cell bioavailability was expressed
148 related to the control (hydrolysis buffer).

149

150 *2.5 Animals*

151 Six-month-old C57BL/6 mice (20-30 g weight) from Envigo (Huntingdom, UK) were
152 housed at the Animal Research Centre of the University in groups of two or three animal

153 per cage with stable room conditions as room temperature (20-24 ºC), 55 ± 10% of
154 humidity and a 12:12 h dark/light cycle. All animals were fed *ad libitum*. Two kinds of
155 diets were used to feed the mice, a standard laboratory animals' diet (Teklad ref. 2014)
156 and a high cholesterol diet (HCD) (Teklad ref. TD.88051), both from Envigo. The animals
157 were supplemented by oral gavage and euthanized at the end of the studies by Oxygen
158 Dioxide and terminal heart puncture. Blood samples were collected to determine plasma
159 lipid profile.

160 The *in vivo* assays with animals were carried out implementing the European
161 Directive 63/2010/EU and the Spanish regulations (RD 53/2013) on animal
162 experimentation. These assays were favourably assessed by the Ethics Committee of the
163 University of Alcalá (CEI: CEI-UAH-AN-2015006) and authorized by the Spanish
164 Competent Authority (PROEX 223/18).

165

166 *2.6 In vivo experiment design*

167 Two sets of *in vivo* assays were designed using two different doses of the olive
168 seed hydrolysate. In all cases, the animals were supplemented once per day, at 10:00 in
169 the morning. In the first study, male and female mice were divided in the following four
170 groups. Group 1 was fed with a standard diet and supplemented with a low concentration
171 of hydrolysate (200 mg/kg/day) while group 2 was supplemented with the same dose but
172 fed with HCD. Group 3 was fed with HCD and supplemented with 5 mg/kg/day of
173 ezetimibe (positive control) while Group 4 was fed with HCD but not supplemented
174 (negative control). Every group was constituted by 9-11 mice with at least 4 female mice
175 per group. Mice blood was collected after 5 and 11 weeks.

176 The second experiment was carried out only with male mice. Three groups were
177 made up: groups 3 and 4 were identical to the previous experiment and a new group
178 (group 5) fed with HCD and supplemented with 400 mg/kg/day of hydrolysate. Every
179 group was constituted by 5-6 mice. In this case, blood was collected after 4 and 8 weeks.

180

181 *2.7 Analyses of mice plasma*

182 Blood samples were collected using Z/Serum separator tubes (Aquisel, Barcelona,
183 Spain) and let 15-30 min at room temperature until blood coagulation. After
184 centrifugation at 1600g for 10 min, serum was collected and storage at -80 ºC until
185 analysis. Serum levels (total cholesterol (TC), total triglycerides (TG), low-density
186 lipoproteins (LDL-C), and high-density lipoproteins (HDL-C)) were determined using
187 routine laboratory methods with a Cobas C311 Autoanalyzer (Roche, Basel,
188 Switzerland). Two indices, atherogenic index (AI) and coronary risk index (CRI), were
189 calculated using the following equations[14]:

190 $$AI = \frac{LDL - C}{HDL - C}$$

191 $$CRI = \frac{TC}{HDL - C}$$

192

193 *2.8 Identification of peptides by HPLC-MS/MS*

194 MS/MS detection was carried out with an electrospray quadrupole-time-of-flight
195 (ESI-Q-TOF) series 6530 mass spectrometer coupled to a liquid chromatograph (model
196 1100), both from Agilent Technologies (Pittsburgh, PA, USA). Analytical separation was
197 carried out in an Ascentis Express Peptide ES-C18 column (100 mm x 2.1 mm, 2.7 µm

198 particle size) with a guard column (5 mm x 2.1 mm, 2.7 µm particle size), both from
199 Supelco (Bellefonte, PA, USA). Mobile phases were: 0.3% (v/v) AA in water (phase A)
200 and 0.3% (v/v) AA in ACN (phase B). Other chromatographic conditions were: injection
201 volume, 15 µL; flow rate, 0.3 mL/min; column temperature, 25 ºC. The elution gradient
202 was: 5% B for 10 min, 5–65% B in 35 min, 65-95% B in 2 min, and 95% B for 3 min. A
203 reversed gradient from 95 to 5% B in 5 min was used to return to the initial eluting
204 conditions.

205 Mass spectrometer was operated in the full-scan mode from 100 to 1500 m/z and
206 in the positive ion mode. ESI conditions were: fragmentator voltage, 200 V; nebulizer
207 pressure, 50 psig; capillary voltage, 3500 V; gas temperature, 350 ºC; drying gas flow, 12
208 L/min; and skimmer voltage, 60 V. The Jet Stream sheath gas temperature was 400 ºC
209 and the flow was 12 L/min. MS/MS was carried out using *Auto* mode with the following
210 conditions: 5 precursors per cycle and a collision energy of 4 V per each 100 Da. Two
211 Agilent compounds (HP0921 and purine) yielding ions at 922.0098 m/z and 121.0509
212 m/z, respectively, were simultaneously introduced and used as internal standards
213 throughout the analysis.

214 PEAKS Studio Version 7 software from Bioinformatics Solutions Inc. (Waterloo,
215 Canada)[15] was used for the analysis of MS/MS spectra and the *novo* sequencing of
216 peptides. Two independent samples of the olive seed hydrolysate were injected by
217 triplicate. Only peptides appearing in the three injections of the two independent samples
218 with average local confidence (ALC, expected percentage of correct amino acids in the
219 peptide sequence) equal or higher than 90 % were selected. Since it is not possible to
220 differentiate between I and L amino acids due to their equal masses, only isoforms with
221 L were presented, although peptide sequences containing I amino acid instead of L are

222 also possible. Isoelectric point and solubility in water were determined using Innovagen's
223 peptide property calculator.

224

225 *2.9 Statistical analysis*

226 Statistical analysis was performed using Statgraphics Software Plus 5.1 (Statpoint
227 Technologies, Inc., Warranton, VA, USA). Data comparison was carried out by the
228 analysis of variance (ANOVA) or the test-t. Duncan's Multiple Range test was used to
229 determine statistically significant differences (p-value < 0.05). Results were expressed as
230 mean ± standard deviation.

231

232 **3. Results and discussion**

233 *3.1 In vitro evaluation of hypocholesterolemic activity*

234 The capacity to reduce the bioavailability of dietary cholesterol and triglycerides
235 of a hydrolysate obtained from olive seed proteins has been explored in a previous work
236 observing a multifunctional effect.[11] Indeed, results demonstrated that the olive seed
237 hydrolysate showed capacity to reduce cholesterol micellar solubility and to inhibit the
238 activity of cholesterol esterase and pancreatic lipase enzymes although it did not show
239 capacity to bind bile acids. Biosynthesis of cholesterol is an additional source of
240 cholesterol that contributes to hypercholesterolemia as much as exogenous cholesterol.
241 Biosynthesis of cholesterol consists of different steps being the transformation of HMG-
242 CoA to mevalonate, the limiting one. This reaction is catalysed by the enzyme HMGR in
243 presence of the cofactor NADPH. Therefore, HMGR is an important target against
244 biosynthesis of cholesterol. *In vitro* HMGR inhibitory activity of the olive seed
245 hydrolysate was determined at two different concentrations and results were compared
246 with that of pravastatin, a drug usually employed for the treatment of
247 hypercholesterolemia (see Figure 1). Olive seed hydrolysate reduced the activity of
248 HMGR in 16.8 % when the peptide concentration was 3.1 mg/mL. This inhibition
249 increased to a 40 % when the peptide concentration was 26.7 mg/mL. This activity is
250 similar to the observed for hydrolysates obtained from amaranth[16] and snakehead fish
251 skin collagen.[17]

252

253

254 *3.2 Cytotoxicity of the olive seed hydrolysate*

255 Safety of the olive seed hydrolysate was determined by the MTT assay using two
256 different human cell lines, a cancer cell line (HeLa cells) and a healthy cell line (HK-2
257 cells). Results shown in Figure 2 demonstrated cytotoxic effects in HeLa cells at
258 concentrations higher than 3 mg/mL and a high cell viability in healthy HK-2 cells at any
259 concentration.

260

261 *3.3 In vivo assay using a low olive seed hydrolysate concentration*

262 Olive seed hydrolysate has showed hypolipidemic activity in *in vitro* assays.
263 Nevertheless, *in vitro* results do not always correlate with *in vivo* capacity since it depends
264 on the bioavailability and temporal and spatial distribution of peptides in the body.[18]
265 Therefore, a first *in vivo* assay was designed to evaluate the physiological effect of the
266 olive seed hydrolysate.

267 A preliminary assay was conducted using male and female mice in order to
268 establish the effect of following a commercial hypercholesterolemic diet in serum lipids.
269 The experiment took 11 weeks and serum TC was determined at week 4, 5, 8, and 11
270 (Figure 3). Both male and female serum TC increased up to weeks 4-5 and, afterwards, it
271 kept up to week 11.

272 From these results, a new set of *in vivo* assays were designed to evaluate the effect
273 of the administration of the olive seed hydrolysate. Four different groups were
274 established: Group 1 was fed with a standard diet and daily treated with 200 mg/kg/day
275 of the olive seed hydrolysate. This dose was selected based on previous studies found in
276 bibliography that used doses ranging from 100 to 2500 mg/kg/day.[19-22] Mice fed with
277 normal diet and daily treated with the olive seed hydrolysate did not show any significant

278 variation in their serum lipids after 5 weeks (data not shown). Moreover, Group 2 was fed
279 with HCD and daily treated with 200 mg/kg/day of the olive seed hydrolysate, Group 3
280 was fed with HCD and daily treated with 5 mg/kg/day of hypocholesterolemic drug
281 ezetimibe, and Group 4 was fed just with HCD. Table 1 shows lipid serum parameters
282 obtained when using male mice. As expected from results in Figure 3, male mice fed with
283 HCD showed a huge increase in TC level after 4 weeks but this level kept up to week 11.
284 The administration of the olive seed hydrolysate reduced this serum TC in male mice in
285 a 17% and a 20% after 5 and 11 weeks of administration, respectively. This result was
286 compared with the obtained for Group 3 (supplemented with ezetimibe) observing that
287 ezetimibe decreased the TC in a 11%, after 11 weeks.

288 A similar experiment was conducted with female mice (see Table 2). The
289 administration of 200 mg/kg/day of the olive seed hydrolysate for 11 weeks in female
290 mice resulted in an increase in serum TC. Moreover, female mice neither showed a
291 significant reduction in serum lipids when they were treated with ezetimibe for 11 weeks.
292 The difference between male and female behaviour could be explained by the different
293 hormonal cycles in the female organism.[23]

294 In addition to TC, serum HDL-C and LDL-C were also determined (see Table 1
295 and 2). HDL-C kept in serum male mice feeding with just HCD after 5 weeks and doubled
296 when the olive seed hydrolysate was administrated for the same period. However, HDL-
297 C levels increased, in the same way, in the groups 2, 3, and 4 after 11 weeks. LDL-C in
298 mice from group 4 increased more than LDL-C in mice from group 2, after 5 weeks. The
299 same effect was appreciated in mice from groups 2 and 4, after 11 weeks. LDL-C levels
300 in mice treated with ezetimibe did not show significant differences with mice from group
301 2. Therefore, the hypocholesterolemic effect of the olive seed hydrolysate, observed after

302 5 and 11 weeks treatment, in male mice seems to be mainly due to the decrease in LDL-
303 C. This effect was similar in the ezetimibe group.

304 Female mice showed an increase in HDL-C when they were treated with the olive
305 seed hydrolysate while no significant variation in HDL-C was observed when they were
306 treated with ezetimibe (see Table 2). This fact could explain the increase in TC observed
307 for female mice treated with the hydrolysate. Female mice LDL-C kept after treatment
308 with hydrolysate while it decreased when they were treated with ezetimibe. This result
309 showed that, for female mice, the hypocholesterolemic effect of the hydrolysate was
310 based on the increase of the HDL-C.

311 Two different indexes, the atherogenic index (AI) and the coronary risk index
312 (CRI), were calculated from lipid serum levels in male and female mice and results are
313 shown in Table 1 and 2. Both, AI and CRI, are strong biomarkers to predict the risk of
314 atherosclerosis and coronary heart diseases and they are more useful than independent
315 serum parameters.[24] Male mice feeding just with HCD resulted in a 215% and a 123%
316 increase in AI and CRI, respectively, after 5 weeks treatment. After 11 weeks, these
317 indexes showed a slight decrease due to the increase of HDL-C level, but they kept
318 significantly higher than the rest of groups. Indeed, AI and CRI indexes in mice from
319 groups supplemented with ezetimibe or hydrolysate were significantly lower than the
320 indexes in the group fed only with HCD. The administration of the olive seed hydrolysate
321 kept AI and CRI indexes in male mice during the whole experiment confirming the
322 hypocholesterolemic effect, at physiological level, of the olive seed hydrolysate.

323 Moreover, no significant variation in TG level was observed in male mice fed
324 with HCD regardless they were treated with hydrolysate or ezetimibe. Similar results
325 were observed for female mice except when they were treated with ezetimibe that resulted
326 in a significant increase in TG level.

327 Taking into account the hypolipidemic effects observed in mice when they were
328 treated with 200 mg/kg/day of the olive seed hydrolysate, a second *in vivo* assay with a
329 higher dose was designed in order to find out whether it can produce a more significant
330 effect.

331

332 *3.4 In vivo assay using a high olive seed hydrolysate concentration*

333 A new *in vivo* assay was carried out using a dose of 400 mg/kg/day of the olive
334 seed hydrolysate and serum lipids were determined after 4 and 8 weeks of treatment.
335 Figure 4 shows TC levels in the group fed with HCD and treated with ezetimibe (Group
336 3), in the group fed with just HCD (Group 4), and in the group fed with HCD and treated
337 with the new concentration of the olive seed hydrolysate (Group 5). As expected, TC
338 increased in three groups after 4 weeks treatment not observing any significant difference
339 in serum TC between them. However, after 8 weeks' treatment, serum TC in mice treated
340 with the olive seed hydrolysate (Group 5) decreased in a 25% while TC in mice within
341 groups 4 and 3 kept at same levels than at week 4. This behaviour has also been observed
342 in Figure 3 and in Table 1. The effect of ezetimibe treatment was observed after treatment
343 for 11 weeks. The effect observed by the administration of 400 mg/kg/day of the olive
344 seed hydrolysate at week 8 (25% reduction in TC) was more significant than the decrease
345 in TC observed when using the dose of 200 mg/kg/day of the olive seed hydrolysate (20%
346 reduction in TC at week 11).

347 Like in the first assay, HDL-C, LDL-C, TG and two indexes were also determined
348 at 8 weeks' treatment (see Table 3). Serum HDL-C increased in the three groups after 8
349 weeks. These increased was higher in mice supplemented with ezetimibe than in mice
350 supplemented with hydrolysate. Furthermore, LDL-C levels decreased in a 44% and 26%

351 in groups 5 and 3, respectively, compared with negative control (group 4). Additionally,
352 both indexes calculated, AI and CRI, were kept at initial values when mice were fed with
353 HCD and supplemented with hydrolysate. The two indexes were significantly lower in
354 mice supplemented with hydrolysate than in mice feeding just HCD. In the case of CRI,
355 after 8 weeks, the index was even slightly lower than at the beginning of the treatment.
356 The mice treated with ezetimibe showed the same AI value than those treated with
357 hydrolysate. However, there was no significant difference in CRI indexes of groups 3 and
358 4. Furthermore, Figure 5 shows the variation of mice weight during the assay in groups 4
359 (HCD), 3 (HCD + ezetimibe), and 5 (HCD + hydrolysate). Animal weight increased in
360 the same way in the three groups. At the end of the assay, all mice increased their body
361 weight above 50%. This fact discards a secondary satiating effect of the olive seed
362 hydrolysate.

363 *In vivo* hypolipidemic effect of the olive seed hydrolysate was similar to the effect
364 observed when purified peptides fractions were employed.[25] Indeed, Rho et al.[26]
365 demonstrated a reduction up to 25% in TC after treatment with a concentrated black
366 soybean hydrolysate fraction for 4 weeks. Nagaoka et al.[2] observed that the administration
367 of a tryptic hydrolysate of the standard protein β-lactoglobulin produced a 17% reduction
368 in TC in 48 h fasted rats. Moreover, Lapphanichayakool, Sutheerawattananonda, and
369 Limpeanchob[26] evaluated the hypocholesterolemic activity of sericin-derived peptides
370 isolated from silk cocoons observing around a 28% TC reduction when a dose of 200
371 mg/kg/day was administrated for 4 weeks. Another example was the work carried out by
372 Zhong et al.[19] that studied the *in vivo* hypocholesterolemic effect of a fraction from a
373 soybean protein hydrolysate. They observed a 24% TC decrease when feeding mice with
374 500 mg/kg/day and no effect when using 100 mg/kg/day doses.

375 In order to estimate the equivalence dose to obtain a similar effect in humans, it
376 is necessary to consider that the metabolism of a high organism is slower than that of a
377 mouse and it is necessary to apply a conversion factor. In the case of a mouse, the
378 conversion factor from animal dose to human dose is 0.081[28]. Then, the human dose
379 necessary to observe a similar effect, considering a 60 kg person, ranges from 0.97-1.9 g.

380

381 *3.5 Identification of peptides potentially responsible for the hypolipidemic effect of the*
382 *olive seed hydrolysate*

383 In order to identify which peptides could be responsible for the observed
384 hypolipidemic effect, the olive seed hydrolysate was analysed by RP-HPLC-MS/MS.
385 Figure 6 shows the EIC (Extracted Ion Chromatogram) and the mass spectra of abundant
386 peptides, FLPH and WNVN. Moreover, Table 4 shows the sequence of the identified
387 peptides along with their molecular masses, retention time, mass accuracy, isoelectric
388 point, and abundance (based on the areas obtained from extracted chromatograms). Only
389 peptides appearing in the three injections of the two independent samples and with ALC
390 equal or higher than 90 % were selected. Thirty-three different peptides with Mw lower
391 than 1 kDa were identified. Identified peptides appeared in the first half of the TIC
392 (between 1-24 min). Peptides had between 4-7 amino acids and showed isoelectric points
393 ranging from 0 to 10. Almost half of peptides showed good solubility in water. Peptides
394 contained a 56% of hydrophobic amino acids (alanine (A), leucine (L), phenylalanine (F),
395 proline (P), methionine (M), valine (V), and tryptophan (W)), 10% of acidic amino acids
396 (glutamic (E) and aspartic (D) acids) and 8% of basic amino acid lysine (K). Most
397 abundant peptides were ADLY, FLPH, KLPLL, and TLVY. Two of these sequences,
398 FDGEVK and VPLSPT, were previously observed, according to BIOPEP-UWM
399 database, and showed antioxidant bioactivities while FAVV, KALM, KGAL, SSPL, and

400 TLVY are part of antibacterial peptides.[29] Some peptides sequences were also observed
401 in previous works of our research group[11,30]. Despite olive seed proteins are not sequenced
402 in proteomic databases (there is no genomic data for the vast majority of olive proteins)
403 yet, it has been possible the comparison of sequenced peptides with proteins identified in
404 a previous work by homology with other plant species[31]. Indeed, two peptides, identified
405 in this work, were within sequences of olive seed proteins: peptide ADIY (the sequence
406 has been observed in protein Triticin OS=Triticum aestivum PE=2 SV=1
407 (tr|B2CGM5|B2CGM5_WHEAT)) and peptide VYIE (the sequence has been observed
408 in 11S globulin seed storage protein 2 OS=Sesamum indicum PE=2 SV=1
409 (sp|Q9XHP0|11S2_SESIN))[31]. Among identified peptides, it is interesting to highlight
410 peptide FDGEVK since it has the same two C-terminal amino acids that a
411 hypocholesterolemic peptide identified in the β-lactoglobulin tryptic hydrolysate.[2]

412 In conclusion a hydrolysate obtained from olive seed proteins using Alcalase
413 enzyme has demonstrated *in vivo* capacity to reduce serum cholesterol in mice at two
414 different concentration levels (200 and 400 mg/kg/day). This effect was attributed to both,
415 the increase of HDL-C and the decrease of LDL-C in serum. The treatment with the olive
416 seed hydrolysate also kept initial atherogenic and coronary risk indexes. According to *in*
417 *vitro* studies, this effect could be attributed to the capability showed by the olive seed
418 hydrolysate to reduce the micellar cholesterol solubility and to inhibit important enzymes
419 (pancreatic lipase, cholesterol esterase, and HMGR) involved in the biosynthesis and
420 absorption of cholesterol. Analysis of mice weight also enabled to discard a possible
421 satiating effect of the hydrolysate. Thirty-three different peptides were identified in the
422 olive seed hydrolysate. All peptides showed a high content of hydrophobic amino acids
423 being peptides ADLY, FLPH, KLPLL, and TLVY the most abundant. These peptides
424 could be responsible for the observed hypolipidemic effect.

425 **Acknowledgments**

426 This work was supported by the Spanish Ministry of Economy and
427 Competitiveness (ref. AGL2016-79010-R) and the Comunidad Autónoma de Madrid and
428 FEDER program (S2018/BAA-4393, AVANSECAL II-CM).

429

430 **References**

431 1. World Health Organization. Cardiovascular diseases (CVDs). Updated May 2017.
432 Geneva, Switzerland: WHO. Available at: http://www.who.int/es/news-room/fact-
433 sheets/detail/cardiovascular-diseases-(cvds).
434 2. Nagaoka, S.; Futamura, Y.; Miwa, K.; Awano, T.; Yamauchi, K.; Kanamaru, Y.; ...
435 Kuwata, T. Identification of novel hypocholesterolemic peptides derived from bovine
436 milk β-lactoglobulin. *Biochem. Biophys. Res. Commun.* **2001**, *281*, 11-17.
437 3. Krause, B. R.; Sliskovic, D. R.; Anderson, M.; Homan, R. Lipid-lowering effects of
438 WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolase. *Lipid.* **1998**, *33*,
439 489-498.
440 4. Insull, J. W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia:
441 a scientific review. *South. Med. J.* **2006**, *99*, 257-273.
442 5. Mattson, F. H.; Beck, L. W. The digestion in vitro of triglycerides by pancreatic
443 lipase. *J. Biol. Chem.* **1955**, *214*, 115-125.
444 6. Goldstein, J. L.; Brown, M. S. Regulation of the mevalonate pathway. *Nature*.
445 **1990**, *343*, 425-430.
446 7. Heidrich, J. E.; Contos, L. M.; Hunsaker, L. A.; Deck, L. M.; Vander Jagt, D. L.
447 Inhibition of pancreatic cholesterol esterase reduces cholesterol absorption in the
448 hamster. *BMC pharmacol*. **2004**, *4*, 670-673.
449 8. Singh, R. B.; Niaz, M. A.; Ghosh, S. Hypolipidemic and antioxidant effects of
450 Commiphora mukul as an adjunct to dietary therapy in patients with
451 hypercholesterolemia. *Cardiovasc. Drugs Ther*. **1994**, *8*, 659-664.
452 9. García, M.C.; Puchalska. P.; Esteve, C.; Marina, M.L. Vegetable foods: A cheap
453 source of proteins and peptides with antihypertensive, antioxidant, and other less
454 occurrence bioactivities. *Talanta*. **2013**, *106*, 328–349.

455 10. Lin, Y. H.; Tsai, J. S.; Chen, G. W. Purification and identification of
456 hypocholesterolemic peptides from freshwater clam hydrolysate with in vitro
457 gastrointestinal digestion. *J. Food Biochem*. **2017**, *41*, e12385.
458 11. Prados, I. M.; Marina, M. L.; García, M. C. Isolation and identification by high
459 resolution liquid chromatography tandem mass spectrometry of novel peptides with
460 multifunctional lipid-lowering capacity. *Food Res. Int*. **2018,** *111*, 77-86.
461 12. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram
462 quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem*.
463 **1976**, *72*, 248-254.
464 13. Marques, M. R.; Freitas, R. A. M. S.; Carlos, A. C. C.; Siguemoto, É. S.; Fontanari,
465 G. G.; Arêas, J. A. G. Peptides from cowpea present antioxidant activity, inhibit
466 cholesterol synthesis and its solubilisation into micelles. *Food Chem.* **2015**, *168*, 288-
467 293.
468 14. Kai, N. S.; Nee, T. A.; Ling, E. L. C.; Ping, T. C.; Kamariah, L.; Lin, N. K. Anti–
469 hypercholesterolemic effect of kenaf (Hibiscus cannabinus L.) seed on high–fat diet
470 Sprague dawley rats. *Asian Pac. J. Tro. Med* .**2015,** *8*, 6-13.
471 15. Ma, B.; Zhang, K.; Hendrie, C.; Liang, C.; Li, M.; Doherty-Kirby, A.; Lajoie, G.
472 PEAKS: powerful software for peptide de novo sequencing by tandem mass
473 spectrometry. *Rapid Commun. Mass Sp*. **2003**, *17,* 2337-2342.
474 16. Soares, R. A. M.; Mendonça, S.; de Castro, L. Í. A.; Menezes, A. C. C. C. C.; Arêas,
475 J. A. G. Major peptides from amaranth (Amaranthus cruentus) protein inhibit HMG-
476 CoA reductase activity. *Int. J. Mol. Sci*. **2015**, *16*, 4150-4160.
477 17. Virginia, A.; Rachmawati, H.; Riani, C.; Retnoningrum, D. S. Study of HMG-CoA
478 Reductase Inhibition Activity of the Hydrolyzed Product of Snakehead Fish (Channa

479 striata) Skin Collagen with 50 kDa Collagenase from Bacillus licheniformis F11.
480 4. *Sci. Pharm*. **2016**, *84*, 81-88.
481 18. Motilva, M.J.; Serra, A.; Rubió, L. Nutrikinetic studies of food bioactive compounds:
482 from in vitro to in vivo approaches, *Int J. Food Sci. and Nutr.* **2015**, *66,* S41-52.
483 19. Zhong, F.; Liu, J.; Ma, J.; Shoemaker, C. F. Preparation of hypocholesterol peptides
484 from soy protein and their hypocholesterolemic effects in mice. *Food Res. Int*. **2007**,
485 *40*, 661-667.
486 20. Liu, C.; Lin, X. L.; Wan, Z.; Zou, Y.; Cheng, F. F.; Yang, X. Q. The physicochemical
487 properties, in vitro binding capacities and in vivo hypocholesterolemic activity of
488 soluble dietary fiber extracted from soy hulls. *Food Funct*. **2016**, *7*, 4830-4840.
489 21. Cheurfa, M.; Allem, R. Study of hypocholesterolemic activity of Algerian Pistacia
490 lenticus leaves extracts in vivo. *Rev. Bras. Farmacogn.* **2015**, *25,* 142-144.
491 22. Khera, N.; Bhatia, A. Antihyperlipedemic activity of Woodfordis fructicos extract in
492 high colesterol diet fed mice. *Int. J. Pharm. Phytopharm. Res.* **2012**, *2,* 211-215.
493 23. Mumford, S. L.; Dasharathy, S.; Pollack, A. Z.; Schisterman, E. F. Variations in lipid
494 levels according to menstrual cycle phase: clinical implications. *Clin. lipidol.* **2011**,
495 *6*, 225-234.
496 24. Millán, J.; Pintó, X.; Muñoz, A.; Zúñiga, M.; Rubiés-Prat, J.; Pallardo, L. F.; Masana,
497 L.; Mangas, A.; Hernández-Mijares, A.; González-Santos, P.; Ascaso, J. F.; … Pedro-
498 Botet, J. Lipoprotein ratios: Physiological significance and clinical usefulness in
499 cardiovascular prevention. *Vasc. Health Risk Manage.* **2009**, *5*, 757-65.
500 25. Howard, A.; Udenigwe, C. C. Mechanisms and prospects of food protein hydrolysates
501 and peptide-induced hypolipidaemia. *Food Funct.* **2013**, *4*, 40-51.

502 26. Rho, S. J.; Park, S.; Ahn, C. W.; Shin, J. K.; Lee, H. G. Dietetic and
503 hypocholesterolaemic action of black soy peptide in dietary obese rats. *J. Sci. Food*
504 *Agric.* **2007**, 87, 908-913.
505 27. Lapphanichayakool, P.; Sutheerawattananonda, M.; Limpeanchob, N.
506 Hypocholesterolemic effect of sericin-derived oligopeptides in high-cholesterol fed
507 rats. *J. Nat. Med*. **2017**, *71*, 208-215.
508 28. Nair, A. B.; Jacob, S. A simple practice guide for dose conversion between animals
509 and human. Journal of basic and clinical pharmacy, **2016**, 7, 27.
510 29. Minkiewicz, P.; Iwaniak, A.; Darewicz, M. BIOPEP-UWM Database of Bioactive
511 Peptides: Current Opportunities. *Int. J Mol*. Sci. **2019**, *20*, 5978.
512 30. Esteve, C.; Marina, M. L.; García; M. C. Novel strategy for the revalorization of olive
513 *(Olea europaea)* residues based on the extraction of bioactive peptides. *Food Chem.*
514 **2015**, *167*, 272-280.
515 31. Esteve, C.; D'Amato, A.; Marina, M. L.; García, M. C.; Citterio, A.; Righetti, P. G.
516 Identification of olive (Olea europaea) seed and pulp proteins by nLC-MS/MS via
517 combinatorial peptide ligand libraries. J proteomics, **2012,** *75*, 2396-2403.

518

519 **Figure captions**

520 **Figure 1.** Capacity of the olive seed hydrolysate to inhibit the enzyme HMGR at two
521 different concentrations (3.1 and 26.7 mg/mL) in comparison with the positive control
522 pravastatin. Means with different letters are significantly different ($p < 0.05$).

523 **Figure 2.** Cell viability of human cell lines HK-2 and HeLa after treatment with the olive
524 seed hydrolysate at different concentrations. Results are expressed as percentage related
525 to the control value. Means with different letters are significantly different ($p < 0.05$).

526 **Figure 3.** Variation of total cholesterol (TC) in serum male and female mice fed with
527 HCD for 11 weeks. Values are expressed as mean ± standard deviation. Means with
528 different letters are significantly different ($p < 0.05$).

529 **Figure 4.** Variation of total cholesterol (TC) in serum male mice fed with HCD (Group
530 3), with HCD and ezetimibe (Group 4), and with HCD and the olive seed hydrolysate
531 (Group 5) after 4 and 8 weeks. Means with different letters are significantly different (p
532 < 0.05).

533 **Figure 5.** Variation of the body weight observed in male mice within Groups 3, 4, and 5
534 during the assay that used 400 mg/kg/day. Means with different letters are significantly
535 different ($p < 0.05$).

536 **Figure 6.** Extracted Ion Chromatograms at 512 m/z (corresponding to peptide FLPH) and
537 531 m/z (corresponding to peptide WNVN) and fragmentation spectra of these peptides.

Table 1. Serum plasma levels in male mice fed with HCD (Group 4) and supplemented with 200 mg/kg/day of hydrolysate (Group 2) or ezetimibe (Group 3). Means with different letters are significantly different ($p < 0.05$).

	WEEK 0	WEEK 5		WEEK 11		
		GROUP 4 (HCD)	GROUP 2 (HCD + Hydrolysate)	GROUP 4 (HCD)	GROUP 2 (HCD + Hydrolysate)	GROUP 3 (HCD + Ezetimibe)
TC	138 ± 17^{a}	274 ± 7^{c}	227 ± 9^{b}	263 ± 9^{c}	209 ± 10^{b}	234 ± 27^{b}
HDL-C	110 ± 6$^{a'}$	97 ± 2$^{a'}$	191 ± 10$^{b'}$	188 ± 9$^{b'}$	177 ± 7$^{b'}$	185 ± 21$^{b'}$
LDL-C	22 ± 5$^{a''}$	61 ± 4$^{cd''}$	48 ± 2$^{bc''}$	66 ± 5$^{d''}$	48 ± 18$^{bc''}$	40 ± 11$^{b''}$
TG	158 ± 36$^{a'''}$	145 ± 14$^{a'''}$	131 ± 26$^{a'''}$	182 ± 35$^{a'''}$	142 ± 45$^{a'''}$	169 ± 31$^{a'''}$
AI	0.20 ± 0.03$^{a''''}$	0.63 ± 0.05$^{c''''}$	0.25 ± 0.00$^{a''''}$	0.35 ± 0.01$^{b''''}$	0.27 ± 0.09$^{a''''}$	0.23 ± 0.03$^{a''''}$
CRI	1.26 ± 0.09$^{a'''''}$	2.82 ± 0.13$^{b'''''}$	1.18 ± 0.02$^{a'''''}$	1.39 ± 0.05$^{b'''''}$	1.18 ± 0.02$^{a'''''}$	1.25 ± 0.06$^{a'''''}$

Table 2. Serum plasma levels in female mice fed with HCD (Group 4) and supplemented with 200 mg/kg/day of hydrolysate (Group 2) or ezetimibe (Group 3). Means with different letters are significantly different ($p < 0.05$).

	WEEK 0	WEEK 11		
		GROUP 4 (HCD)	**GROUP 2 (HCD + Hydrolysate)**	**GROUP 3 (HCD + Ezetimibe)**
TC	93 ± 6^{a}	122 ± 26^{b}	160 ± 24^{c}	118 ± 11^{ab}
HDL-C	$75 \pm 4^{a'}$	$108 \pm 24^{b'}$	$137 \pm 29^{c'}$	$98 \pm 9^{b'}$
LDL-C	$19 \pm 3^{b''}$	$19 \pm 4^{b''}$	$24 \pm 7^{b''}$	$12 \pm 4^{a''}$
TG	$131 \pm 35^{a'''}$	$182 \pm 53^{a'''b'''}$	$164 \pm 13^{a'''b'''}$	$315 \pm 42^{b'''}$
AI	$0.25 \pm 0.03^{b''''}$	$0.18 \pm 0.01^{a''''b''''}$	$0.17 \pm 0.02^{a''''}$	$0.12 \pm 0.04^{b''''}$
CRI	$1.25 \pm 0.05^{c'''''}$	$1.12 \pm 0.06^{b'''''}$	$1.05 \pm 0.28^{b'''''}$	$1.20 \pm 0.06^{a'''''}$

le mice fed with HCD (Group 4) and supplemented with 400 mg/kg/day of hydrolysate (Group 5) or ezetimibe

ers are significantly different ($p < 0.05$).

WEEK 8		
GROUP 4 (HCD)	GROUP 5 (HCD + Hydrolysate)	GROUP 3 (HCD + Ezetimibe)
259 ± 61^{c}	194 ± 31^{b}	271 ± 23^{c}
$71 \pm 20^{c'}$	$172 \pm 36^{b'}$	$213 \pm 20^{c'}$
$62 \pm 17^{c''}$	$35 \pm 6^{b''}$	$46 \pm 11^{b''}$
$65 \pm 36^{a'''}$	$163 \pm 75^{a'''}$	$141 \pm 27^{a'''}$
$31 \pm 0.04^{b''''}$	$0.21 \pm 0.02^{a''''}$	$0.24 \pm 0.02^{a''''}$
$18 \pm 0.07^{b'''''}$	$1.14 \pm 0.04^{a'''''}$	$1.28 \pm 0.04^{b'''''}$

Table 4. Peptide sequence, average local confidence (ALC), retention time, molecular mass, mass accuracy (ppm), isoelectric point, water solubility, and abundance of peptides sequenced in the olive seed hydrolysate.

PEPTIDE	ALC (%)	RT	MASS	PPM	ISOELECTRIC POINT	SOLUBILITY IN WATER	ABUNDANCE ($X10^6$)
ADLY	92	9.63	480.222	-3.8	0.74	Good	115.3 ± 7.9
AVFDD	95	13.73	565.2383	-5.1	0.73	Good	47.8 ± 4.4
FAVV	94	21.32	434.2529	-5.2	0.00	Poor	9.8 ± 0.7
FDGEVK	96	4.46	693.3333	-6.4	3.93	Good	75.1 ± 7.3
FLPH	93	9.69	512.2747	-5.1	0.10	Poor	306.2 ± 8.9
HTLY	92	5.02	532.2645	-5.4	0.10	Poor	36.5 ± 2.8
KALM	96	3.24	461.2672	-4	9.91	Good	15.9 ± 0.9
KFVEGDE	90	8.89	822.3759	-7.7	3.69	Good	7.3 ± 0.5
KGAL	94	1.56	387.2481	-2.9	9.91	Good	20.5 ± 1.9
KLGNF	93	16.03	577.3224	-7.6	9.91	Good	33.3 ± 0.8
KLPL	97	18.9	469.3264	-5.9	9.91	Good	86.3 ± 4.0
KLPLL	96	23.78	582.4105	-7	9.91	Poor	193.4 ± 10.8
KVSSPL	93	12.37	629.3748	-7.7	9.91	Good	22.1 ± 2.7
LAFK	93	9.13	477.2951	-7.8	10.12	Good	3.4 ± 1.3
LLGL	94	23.36	414.2842	-7.5	3.63	Poor	4.2 ± 0.6
LPVNTL	92	22.04	655.3904	-7.2	3.63	Poor	13.8 ± 2.1
NDVFK	94	6.06	621.3122	-6	6.22	Good	14.7 ± 2.1
NFVVLK	93	21.11	718.4377	-7.7	9.70	Poor	53.0 ± 7.5
SSPL	92	5.18	402.2114	-3.2	3.37	Poor	15.1 ± 1.2
SSPLL	96	20.18	515.2955	-6.1	3.37	Poor	20.4 ± 2.9
STLF	94	21.42	466.2427	-6.6	3.43	Poor	28.2 ± 4.5
SVLY	94	17.6	480.2584	-5.3	3.39	Poor	96.3 ± 8.6
TLVY	95	17.97	494.274	-5.3	3.35	Poor	177.7 ± 15.1
VDLE	96	7.51	474.2325	-3.9	0.71	Good	11.3 ± 0.7
VFDGE	93	7.28	565.2383	-5.1	0.71	Good	20.1 ± 3.4
VPLSPT	96	15.35	612.3483	-6.5	3.66	Poor	94.3 ± 7.1
VVLK	99	2.55	457.3264	-2.5	10.10	Good	11.5 ± 0.5
VVLLT	92	20.89	543.3632	-7	3.66	Poor	6.6 ± 0.4
VVVPH	90	7.3	549.3275	-6.9	7.78	Poor	12.1 ± 1.2
VYLE	92	15.37	522.2689	-4.2	1.00	Good	12.1 ± 1.9
WDPN	91	5.92	530.2125	-3.2	0.78	Good	30.7 ± 3.4
WNVN	91	13.91	531.2441	-6	3.59	Poor	75.5 ± 7.2
YTSSPL	94	18.27	666.3224	-7.3	3.34	Poor	27.8 ± 4.2



Fig. 1



Fig. 2



Fig. 3



Fig. 4



Group 3	a	a'	a''b''	ab'''	b''''	a'''''	a''''''
Group 4	b	b'	b''	b'''	b''''	a'''''	a''''''
Group 5	ab	a'b'	a''	a'''	a''''	a'''''	a''''

Fig. 5



Fig. 6

For Table of Contents Only